<qa>  What is the name of the Phase III study?This a Phase III, double-blind, placebo-controlled, multi-center study of intravenous OvaRex MAb-B43.13 as post-chemotherapy consolidation for epithelial carcinoma of ovarian, tubal, or peritoneal origin. 